Bristol-Myers Squibb released pooled efficacy and safety results from the Phase III CheckMate -017 and CheckMate -057 trials in patients with previously treated advanced NSCLC.
Shares of Acadia Pharmaceuticals were up nearly 70 percent after a Phase III psychosis trial was halted early as the Parkinson’s disease drug Nuplazid hit primary endpoints, positioning the company to seek another potential regulatory approval.
Neurotrope Inc.’s shares tumbled nearly 80 percent after the company said the drug developer’s experimental Alzheimer’s disease treatment Bryostatin-1 did not meet the main goal of a mid-stage study.
Lilly’s targeted RET drug shrinks tumors in lung cancer trial
Acquisitions, Advanced lung cancer, Business, Clinical Trials, European Society for Medical Oncology (ESMO), FDA, Gene Abnormalities, Liver Enzymes, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, R&D, RET Gene, Tumor Shrinkage, Tumors, World Conference on Lung CancerEli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
Amgen drug shrinks lung cancer tumors in half of patients: study
Advanced lung cancer, Cancer Cells, Cancer Deaths, Checkpoint Inhibitors, Chemotherapy, Clinical Data, Clinical Trials, Colorectal Cancer, Genetic Mutations, Immune System, KRAS Mutations, Non-Small Cell Lung Cancer, R&D, Tumor Shrinkage, Wall Street, World Conference on Lung CancerAn experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
People who get even a small amount of exercise may be less likely to die prematurely than their more sedentary counterparts, a research review suggests.
Ardelyx’s Phase III AMPLIFY study of tenapanor achieved the clinical trial’s primary endpoint, as well as all key secondary endpoints, in treating patients with chronic kidney disease (CKD).
AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.
In a late-stage study, Genentech’s flu drug Xofluza showed significant efficacy as a preventative treatment.
AbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer.
